Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIANEAL 137 W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIANEAL 137 W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Removes waste products (e.g., urea, creatinine) and excess electrolytes via diffusion and ultrafiltration across the peritoneal membrane; dextrose acts as osmotic agent to generate ultrafiltration.
Creates an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and diffusion of solutes (e.g., urea, creatinine, electrolytes) from blood into the dialysate, which is then drained.
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges daily, as part of continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal (IP) administration: 2 liters per exchange, 4 exchanges daily, with dwell time of 4-6 hours. Dextrose concentration (2.5%) selected based on ultrafiltration needs.
None Documented
None Documented
Not applicable; dextrose is rapidly metabolized (half-life ~2-5 min), electrolytes are distributed and excreted renally with half-life dependent on renal function.
Not applicable as a single entity; the dextrose component has a plasma half-life of approximately 15-20 minutes after absorption, reflecting rapid insulin-mediated clearance.
Renal: 100% (electrolytes and dextrose are completely reabsorbed or metabolized; water is excreted renally). Biliary/fecal: 0%.
Primarily excreted via peritoneal dialysis fluid removal; glucose is metabolized systemically. Renal excretion negligible as dialysis solution is not absorbed significantly. Fecal excretion minimal.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution